Polyphor's Sfr116m float to fight anti-microbial resistance
Polyphor, the Swiss pharmaceutical company, began bookbuilding on Friday for its IPO on the SIX Swiss Exchange, with a price range that values it at up to Sfr401m.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: